Kiniksa reports ARCALYST 2023 net revenue $233.1M; abiprubart Phase 2 meets primary endpoint

Kiniksa Pharmaceuticals International, plc

ARCALYST 2023 net product revenue $233.1M, up ~90% YoY; Q4 2023 revenue $71.2M.
2024 ARCALYST net product revenue guidance set at $360M-$380M.
Abiprubart Phase 2 RA trial met primary endpoint at 5 mg/kg weekly dose (p=0.0487); 5 mg/kg biweekly missed.
Cash, equivalents, and short-term investments $206.3M expected to fund operations into at least 2027.
~9% of target 14,000 multiple-recurrence pericarditis patients on ARCALYST; salesforce expanded to ~85 reps.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kiniksa Pharmaceuticals International, plc reported the fourth quarter and full year 2023 results: revenue ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaud. Guidance initiated.

Period: the fourth quarter and full year 2023
Revenue: ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaud
Guidance: initiated
Result: preliminary results

Exact text from the filing

On January 4, 2024, Kiniksa Pharmaceuticals, Ltd. (the “Company”) issued a press release (the “Press Release”) announcing, among other things, that (i) its preliminary year-end 2023 cash, cash equivalents and short-term investments of $206.3 million (unaudited) are expected to fund its current operating plan into at least 2027 and (ii) ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaudited).

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-24-001149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.